Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes
{{output}}
Background: Limited data exist on the burden of myeloproliferative, lymphocytic and idiopathic subtypes of hypereosinophilic syndrome (M-HES, L-HES and I-HES) and the characteristics of patients with HES receiving biologic therap... ...
